Market Access News | pharmaphorum

News

Woman in protective clothing in a laboratory

Report says AZ's UK plant decision is not just about funding

It's been reported that the UK government made an offer of £78 million in funding for AstraZeneca's abandoned £450 million vaccine facility in Speke.

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

CHMP backs Bavarian Nordic's chikungunya jab

Bavarian Nordic is likely just weeks away from bringing the second chikungunya vaccine to the EU, and the first approved for use in adolescents.

News

AstraZeneca abandons plan for £450m vaccine plant in UK

In a shock move, AstraZeneca has ditched its plan to invest £450m in a new vaccine manufacturing plant in the UK.

News

EMA experts will look again at Leqembi's safety data

It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi.

News

Sickle cell gene therapy Casgevy finally cleared for NHS use

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

Report says AZ's UK plant decision is not just about funding

Boost to Enhertu's prospects as FDA clears Roche diagnostic

CHMP backs Bavarian Nordic's chikungunya jab

AstraZeneca abandons plan for £450m vaccine plant in UK

EMA experts will look again at Leqembi's safety data

Sickle cell gene therapy Casgevy finally cleared for NHS use

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks